Fineline Cube

Follow:
14420 Articles
NMPA Releases Draft Measures on Drug Quality Sampling, Seeks Public Comments by Nov 5
Policy / Regulatory

NMPA Releases Draft Measures on Drug Quality Sampling, Seeks Public Comments by Nov 5

Novartis Asciminib Enters China’s SPARK Program for Pediatric Chronic Myeloid Leukemia
Policy / Regulatory

Novartis Asciminib Enters China’s SPARK Program for Pediatric Chronic Myeloid Leukemia

WuXi AppTec Sells WuXi Clinical and MedKey to Hillhouse for RMB 2.8 Billion
Others

WuXi AppTec Sells WuXi Clinical and MedKey to Hillhouse for RMB 2.8 Billion

Wuxi Apptec Reports 15.3 % YoY Revenue Growth in Q3 2025, Net Profit Hits RMB 4.22 Billion
Company

Wuxi Apptec Reports 15.3 % YoY Revenue Growth in Q3 2025, Net Profit Hits RMB 4.22 Billion

Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression
CompanyDrug

Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression

Novartis Strikes USD 12b Deal for Avidity’s RNA Therapeutics and Gene-Targeted Pipeline
CompanyDeals

Novartis Strikes USD 12b Deal for Avidity’s RNA Therapeutics and Gene-Targeted Pipeline

Eli Lilly to Acquire Adverum Biotechnologies for Up to USD 261.7m for Ixo-vec Access
CompanyDeals

Eli Lilly to Acquire Adverum Biotechnologies for Up to USD 261.7m for Ixo-vec Access

Alphamab Oncology's JSKN003 Approved for Phase III Trial in HER2-Positive CRC
CompanyDrug

Alphamab Oncology’s JSKN003 Approved for Phase III Trial in HER2-Positive CRC

AstraZeneca Launches Sixth Global R&D Center in Beijing to Accelerate China Investments
CompanyDeals

AstraZeneca Launches Sixth Global R&D Center in Beijing to Accelerate China Investments

Chiesi Group Launches First EB Wound Treatment in China
CompanyDrug

Chiesi Group Launches First EB Wound Treatment in China

Chugai to Acquire Renalys Pharma for JPY 31 Billion to Expand IgA Nephropathy Treatment Portfolio
CompanyDeals

Chugai to Acquire Renalys Pharma for JPY 31 Billion to Expand IgA Nephropathy Treatment Portfolio

Innovent's Mazdutide Meets Phase III Endpoint in Type 2 Diabetes and Obesity Trial
CompanyDrug

Innovent’s Mazdutide Meets Phase III Endpoint in Type 2 Diabetes and Obesity Trial